PREVENTROP

New approach to treatment of the blinding disease Retinopathy of Prematurity (ROP)

 Coordinatore GOETEBORGS UNIVERSITET 

 Organization address address: VASAPARKEN
city: GOETEBORG
postcode: 405 30

contact info
Titolo: Dr.
Nome: Ellen
Cognome: Rydberg
Email: send email
Telefono: +46 31 7866470
Fax: +46 31 7864355

 Nazionalità Coordinatore Sweden [SE]
 Totale costo 7˙590˙759 €
 EC contributo 5˙990˙236 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2012-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-10-01   -   2017-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    GOETEBORGS UNIVERSITET

 Organization address address: VASAPARKEN
city: GOETEBORG
postcode: 405 30

contact info
Titolo: Dr.
Nome: Ellen
Cognome: Rydberg
Email: send email
Telefono: +46 31 7866470
Fax: +46 31 7864355

SE (GOETEBORG) coordinator 874˙314.41
2    SMERUD MEDICAL RESEARCH INTERNATIONAL AS

 Organization address address: DRAMMENSVEIEN 41
city: OSLO
postcode: 271

contact info
Titolo: Ms.
Nome: Christine
Cognome: Engebretsen
Email: send email
Telefono: +47 2327 2000

NO (OSLO) participant 805˙200.00
3    PREMACURE AB

 Organization address address: DAG HAMMARSKJOLDS VAG 60
city: UPPSALA
postcode: 751 83

contact info
Titolo: Mr.
Nome: Jan
Cognome: Borg
Email: send email
Telefono: +46 706 502 852

SE (UPPSALA) participant 790˙160.99
4    LUNDS UNIVERSITET

 Organization address address: Paradisgatan 5c
city: LUND
postcode: 22100

contact info
Titolo: Prof.
Nome: David
Cognome: Ley
Email: send email
Telefono: +46 46 2220000

SE (LUND) participant 679˙896.00
5    CHILDREN'S HOSPITAL CORPORATION

 Organization address address: LONGWOOD AVENUE 300
city: BOSTON
postcode: 2115

contact info
Titolo: Ms.
Nome: Seshadri
Cognome: Shilpa
Email: send email
Telefono: +1 617 919 2529

US (BOSTON) participant 644˙745.00
6    KAROLINSKA INSTITUTET

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Dr.
Nome: Trana
Cognome: Rolf
Email: send email
Telefono: +46 8 524 877 41

SE (STOCKHOLM) participant 528˙489.20
7    Academisch Medisch Centrum bij de Universiteit van Amsterdam

 Organization address address: MEIBERGDREEF 9
city: AMSTERDAM
postcode: 1105AZ

contact info
Titolo: Ms.
Nome: G
Cognome: Yalvac
Email: send email
Telefono: +31 20 566 6265

NL (AMSTERDAM) participant 461˙448.00
8    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

 Organization address address: The Old Schools, Trinity Lane
city: CAMBRIDGE
postcode: CB2 1TN

contact info
Titolo: Ms.
Nome: Renata
Cognome: Schaeffer
Email: send email
Telefono: +44 1223 333543
Fax: +44 1223 332988

UK (CAMBRIDGE) participant 461˙448.00
9    ISTITUTO GIANNINA GASLINI

 Organization address address: VIA GEROLAMO GASLINI 5
city: GENOVA
postcode: 16147

contact info
Titolo: Dr.
Nome: Maria Gabriella
Cognome: Marinari
Email: send email
Telefono: +39 010 563 6805

IT (GENOVA) participant 421˙454.40
10    MEDIAGNOST GESELLSCHAFT FUR FORSCHUNG UND HERSTELLUNG VON DIAGNOSTIKA GMBH

 Organization address address: ASPENHAUSTRASSE 25
city: REUTLINGEN
postcode: 72770

contact info
Titolo: Dr.
Nome: Angelika
Cognome: Haage
Email: send email
Telefono: +49 7121 414840

DE (REUTLINGEN) participant 323˙080.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

rare    blindness    drug    prematurity    premiplex    reg    preterm    infants    designated    care    morbidity    rop    clinical    affecting    survival    medicinal    morbidities    retinopathy    life    orphan    disease    severe   

 Obiettivo del progetto (Objective)

'The overall objective is to develop a novel preventative intervention for the blinding disease retinopathy of prematurity (ROP) and other complications of prematurity. The PREVENTROP consortium proposes to conduct preclinical studies (pharmacological, pharmacodynamics, pharmacokinetics and toxicological) in models and/or clinical studies (including phase III clinical trial) of an EU designated orphan medicinal product. This orphan medicinal product has been granted the EU orphan designation. We have completed both a Phase I study and the first section of the Phase II study administering the growth factor complex IGF-I/IGFBP-3 (Premiplex®) successfully to preterm infants in order to prevent ROP– a discovery that we have taken from bench to bedside. Due to improved neonatal care, the survival of preterm babies has increased dramatically during the last decades. The downside of this improvement in survival rates is higher morbidity affecting these vulnerable infants. It should be emphasised that in a preterm infant any lasting morbidity will have a negative impact on the quality of life for a whole life span for both the individual and their families. One of the most severe morbidities affecting these infants is retinopathy causing severe visual impairment and blindness. Our research findings have rendered several editorials pointing at the hope of prevention strategies which if successful will change the paradigm for ROP and other morbidities in preterm infants. There are three major impacts of the present proposal; (1) clinical availability of a new orphan designated drug product, Premiplex®, and (2) improved care of preterm infants and (3) a significant contribution towards the goal of the International Rare Disease Research Consortium (IRDiRC) by delivering one new therapy for a rare disease.'

Introduzione (Teaser)

A large multi-disciplinary European consortium is underway to develop a novel drug for preventing blindness in prematurely born infants.

Altri progetti dello stesso programma (FP7-HEALTH)

PANCARELIFE (2013)

"PanCare Studies in Fertility and Ototoxicity to Improve Quality of Life after Cancer during Childhood, Adolescence and Young Adulthood"

Read More  

CARS EXPLORER (2008)

"Innovative contrast imaging by non-linear optics (NLO) for the observation of biological tissues in vivo and in real time, at cellular and molecular levels"

Read More  

INCOMB (2008)

"Combating incontinence, from basic science to clinical practice"

Read More